Appeals court splits over embryonic stem cells


The three-judge panel on a federal appeals court considering whether to overturn a ban on federal funding of embryonic stem cell research revealed a split during a hearing yesterday.

President Barack Obama’s administration is appealing a lower court decision banning federal funding of the research. During yesterday’s hearing at the U.S. Court of Appeals for the District of Columbia Circuit, two of the judges questioned the U.S. Justice Dept.’s arguments that the ban would do irreparable harm to the public interest, while a third seemed more sympathetic.

Judge Royce Lamberth of the U.S. District Court for the District of Columbia had ruled that federal funds could not be used for the the research, derailing scores of projects looking into the causes of diseases like Parkinson’s, Alzheimer’s and cystic fibrosis. Obama had sought to restore stem cell research funding from constraints imposed under the Bush administration, but Lamberth ruled that the policy violated the Dickey-Wicker Amendment, aimed at stopping the destruction of human embryos.

But Dickey-Wicker proved to be a sticky wicket for both plaintiffs and defendants when the appeals court issued a temporary stay of the Lamberth ruling.

Obama’s policy allowed the use of stem cell lines derived from frozen embryos from fertility treatments that were no longer needed and donated according to stringent ethical guidelines. The plaintiffs in the lawsuit, James Sherley and Theresa Deisher, argued that the Obama policy violated the Dickey-Wicker rules.

Beth Brinkmann, a Justice Dept. lawyer, argued that the ban would be a waste of the $64 million that’s already been spent on 24 research projects at the National Institutes of Health, according to news reports. Thomas Hungar, an attorney for the plaintiffs, called that argument speculation and maintained that no injury is imminent or irreversible.

Judge Thomas Griffith, a George W. Bush appointee, appeared to be the most skeptical of the government’s argument, saying that the judges are not hearing the case to decide the wisdom of government policy but to judge whether the research violates the Dickey-Wicker amendment.

“All $64 million is completely ruined?” Griffith asked. “They don’t keep lab notebooks?”

There are notes, Brinkmann said, but “it would be a setback for the field. Biological material would be destroyed.”

Judge Brett Kavanaugh, another George W. Bush appointee, called the government’s position “odd” and “internally inconsistent” but said it might be best to defer to the government’s arguments because of the ambiguity of the Dickey-Wicker statute.

Clinton appointee Judge Judith Rogers said that even a temporary halt to the funding could damage public interest represented by the research.

The Justice Dept. previously argued that Congress never intended for the Dickey-Wicker rules to bar all embryonic stem cell research.

"The National Institutes of Health has funded research using embryonic stem cells since 2002, and has not interpreted the Amendment to bar such grants,” according to court documents. "Fully aware of NIH practice, Congress has used the same language in reenacting the funding limitation, and has repeatedly made clear that NIH’s practice is consistent with the statute. Indeed, the relevant Committee Report for the 2010 appropriations bill, enacted after issuance of the current NIH guidelines, noted that the bill ‘should not be construed to limit Federal support for research involving human embryonic stem cells carried out in accordance with policy outlined by the President.’"

That’s because research using stem cell lines already in existence doesn’t involve the destruction of the embryos, the DOJ argued.

"The bar posited by plaintiffs and the district court has never existed," according to the documents. "[R]esearch using embryonic stem cells is not ‘research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death.’ Plaintiffs insist that this consistent interpretation reflects a ‘warped reading of the term "research,"’ which should be understood to mean a ‘systematic investigation.’ Referring to scientific research projects as ‘systematic investigations’ adds nothing to plaintiffs’ argument and does not expand research funded by NIH to include antecedent acts that were not funded by NIH."

Furthermore, the Justice Dept. argued, barring federal funding of the research will have a catastrophic impact on medical research.

"Disruption of ongoing research will result in irreparable setbacks and, in many cases, may destroy a project altogether. In contrast, the two plaintiff scientists identify no imminent irreparable injury," according to the department.

RSS From Medical Design & Outsourcing

  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]
  • First ‘Ear Wear’ for Active Adults Debuts with MDHearingAid FIT
    If you’ve burned out your ears with earbuds, headphones or decades of other audio abuse but aren’t ready for your grandmother’s hearing aids, not to worry! The new MDHearingAid FIT gets you back in the game with a tiny, FDA-registered, one-size-fits-most solution that doesn’t block your ear canal like old-fashioned in-the-ear hearing aids. The FIT feels […]
  • CardioGenics enters into manufacturing agreement with Ontario-based Plasticap
    CardioGenics Holdings, developer for the In-Vitro-Diagnostics (“IVD”) testing market, announced that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics’ proprietary self-metering cartridges for its QL Care analyzer. The term of the agreement is three years and the purchase price for each cartridge shall be […]
  • MTD Micro Molding releases micro materials menu
    MTD Micro Molding, a long-time leader in micro-injection molding, has released an updated “Materials Menu” of materials that can be successfully micromolded to help guide engineers at medical device companies. Material selection is a crucial step in product manufacturability. The correct material drives tolerance, dimension, strength, usabality, speed-to-market, design, critical features, and cost. Through MTD’s […]
  • MedTech Chat: Elastic technology for drug delivery
    Dr. Zhen Gu and Dr. Yong Zhu from North Carolina State University are both co-senior authors of a research paper describing their recent work. Dr. Gu, Dr. Zhu and other researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug delivery technology that consists of an […]
  • B. Braun’s OEM Division offers large bore normally closed low-pressure check valves
    Infusion therapy and pain management device manufacturer B. Braun said today it is offering normally closed large-bore low-pressure check valves through its valve-focused contract manufacturing OEM division. The valves, offered by Bethlehem, Pa.-based B. Braun, are designed for the intermittent injection of fluids during medical treatment and open automatically when pressure is applied. The newly […]
  • Continuous 225W with natural convection for medical type BF power supply
    Powerbox, a European power supply company, introduces new Medline 225 series ac and dc single output open frame converters for medical type BF applications. The new OFM225 with its 3 x 5 in. footprint and 1.5 in. height is designed for a continuous output power of 225W with natural convection and 40°C ambient temperature, increasing to […]
  • Using data science to achieve ultra-low dose CT image reconstruction
    Prof. Jeff Fessler and Prof. Yong Long, Ph.D. of the University of Michigan-Shanghai Jiao Tong University (UM-SJTU) Joint Institute are collaborating on a project to develop a dramatically improved approach to low-dose X-ray CT image formation by extracting and using information from a big-data corpus of regular dose X-Ray Computed Tomography (CT) images. The research is […]

Leave a Reply